News

Take a look at the long-term effects of stimulant medications on ADHD, specifically tolerance and its implications for treatment efficacy.

Digital therapeutics revolutionize health care by enhancing patient outcomes through technology and offering scalable, evidence-based treatments for various conditions.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a favorable safety profile and potential for rapid relief.

Explore the unique benefits of Ingrezza, a VMAT2 inhibitor for tardive dyskinesia, and how it compares to other treatment options.

Discover how objective testing transforms ADHD diagnosis and treatment, enhancing accuracy and accessibility for adults in hybrid care settings.

At-home transcranial magnetic stimulation offers a safe, effective way to treat depression, enhancing access and reducing reliance on medications.

Jail diversion programs offer vital support for individuals with mental health and substance use disorders, promoting recovery and reducing recidivism.

Let's investigate the complexities of diagnosing and treating ADHD in older adults, highlighting its prevalence, comorbidities, and treatment challenges.

This article is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., for which Dr. Ann Childress is a paid consultant.

Tonmya, a groundbreaking fibromyalgia treatment, is now available in the US, offering hope for millions suffering from chronic pain.

Misinformation about ADHD impacts treatment and self-perception. This Special Report clarifies misconceptions, promotes understanding, and supports informed care for individuals with ADHD.

AI can transform the tedious task of writing progress notes for psychiatrists, offering both efficiency and challenges in clinical practice.

Chatbots risk validating suicidal thoughts, highlighting the urgent need for ethical programming to prioritize user safety and human connection.

Explore the emerging field of spiritual psychiatry, addressing the intersection of mental health, ethics, and personal meaning in patient care.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Recent studies suggest lithium may effectively prevent cognitive decline and Alzheimer disease, challenging the dominance of lecanemab in early dementia treatment.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Explore the transformative potential of futures thinking in mental health, offering innovative frameworks to navigate uncertainty and enhance agency.

Explore the evolving role of lamotrigine in treating bipolar depression, highlighting its benefits, risks, and recent clinical guidelines.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Two promising psychiatrists have tragically passed away.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."

FDA committee discusses potential and risks of AI-enabled digital mental health devices.

A recent study links lower income to higher dementia risk factors, highlighting the need for targeted interventions in vulnerable populations.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.